Summary

Overview
The global prostate health market reached US$ 41.34 billion in 2024 and is expected to reach US$ 99.41 billion by 2033, growing at a CAGR of 9.1% during the forecast period 2025-2033.
Prostate health is a vital aspect of men's overall well-being, particularly as they age. The most common prostate-related issues include prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. These conditions can lead to significant symptoms such as painful urination, frequent urges to urinate, and pelvic discomfort.
The prostate health market is expanding rapidly due to the increasing prevalence of these conditions and a growing aging population. Treatment options vary depending on the specific condition and may include medications like alpha-blockers and 5-alpha-reductase inhibitors for BPH, antibiotics for prostatitis, and various therapies for prostate cancer, including surgery, radiation therapy, and hormone treatments. As awareness of prostate health issues increases, the demand for effective diagnostic tools and therapeutic interventions increases.
Market Dynamics: Drivers & Restraints
Increasing Prevalence of Prostate Disorders
The rising prevalence of prostate disorders, particularly benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis, is a significant driving force behind the growth of the prostate health market. As prostate disorders become more common, especially among the aging male population, there is an increasing demand for effective diagnostic and therapeutic solutions.
Prostate cancer, being the most prevalent cancer among men globally, contributes to millions of new cases each year. For instance, according to the estimates by the American Cancer Society, it is stated that about 313,780 new cases of prostate cancer are expected to be reported in 2025.
Additionally, according to the European Association of Urology in 2024, it is stated that about 2-6% of all men are affected. This surge in prevalence not only heightens awareness and concern about prostate health but also propels investments in research and development for new treatments and technologies. Thus, the above factors are expected to drive market growth during the forecast period.
Adverse Effects of Treatments
Adverse effects of treatments for prostate health, particularly for conditions like prostate cancer, are significant restraints on the prostate health market. A substantial percentage of patients experience long-term complications following various treatment modalities. The risks associated with these treatments can be daunting; men who undergo prostatectomy face a sevenfold increase in urinary or sexual complications compared to untreated individuals. Additionally, radiotherapy can lead to bowel dysfunction and increases the risk of secondary cancers, such as bladder cancer, by nearly three times compared to untreated men
Segment Analysis
The global prostate health market is segmented based on indication, treatment, end users, and region.
Treatment:
Hormone Therapy segment is expected to dominate the global prostate health market share
The prostate health market is expected to see significant growth, driven primarily by the increasing prevalence of prostate cancer and the rising demand for effective treatment options. Among the various treatment modalities available, hormone therapy is projected to hold a dominant position in the prostate health market.
Currently, hormone therapy is recognized as the leading treatment for prostate cancer due to its effectiveness in managing advanced stages of the disease, particularly in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHNPC). Companies are receiving approvals for their innovations and are meeting the regulatory needs and demands. For instance, in October 2023, Sumitomo Pharma Canada, Inc. its ORGOVYX (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist received approval from Health Canada. The approval is based on efficacy and safety data from the Phase 3 HERO study of ORGOVYX in men with advanced prostate cancer.
Additional factors contributing to its dominance include a growing geriatric population, advancements in drug formulations, and an increase in public awareness regarding prostate health.
Geographical Analysis
North America is expected to hold a significant position in the global prostate health market share
North America dominates the prostate health market due to several key factors contributing to its substantial market share. The region has a high incidence of prostate-related conditions, including benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. This growing target population drives demand for effective diagnostic and therapeutic solutions.
Additionally, North America benefits from a robust healthcare infrastructure, which includes advanced medical facilities and a strong presence of leading medical device manufacturers, fostering innovation and product development. For instance, in June 2023 AstraZeneca and Merck received U.S. FDA approval for its LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
In August 2023, the Janssen Pharmaceutical Companies received the U.S. Food & Drug Administration (FDA) approval for its AKEEGA (niraparib and abiraterone acetate) for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test. It is the first and only dual-action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone. Collectively, these factors position North America in a dominant position in the prostate health market.
Competitive Landscape
The major global players in the prostate health market include Novartis AG, GSK plc., Astellas Pharma Inc., Merck & Co., Inc., JOHNSON & JOHNSON SERVICES, INC., Pfizer Inc., Sanofi SA, Bayer, Zydus Lifesciences Limited and Wellona Pharma among others.
Key Developments
• In December 2024, Candel Therapeutics, Inc. announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized prostate cancer patients.
• In 2024, Bayer announced that the U.S. Food and Drug Administration (FDA) had accepted the company’s supplemental new drug application (sNDA) for the oral androgen receptor inhibitor (ARi) NUBEQA (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
• In April 2023, The Janssen Pharmaceutical Companies announced the availability of an additional tablet strength of ERLEADA (apalutamide) in the United States.
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Global Prostate Health Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.

• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.

• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.

• Supply Chain: Distribution and Supply Chain Managers.

• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.

• Academic & Research: Academic Institutions.

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Indication
3.2. Snippet by Treatment
3.3. Snippet by End Users
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of benign prostatic hyperplasia
4.1.2. Restraints
4.1.2.1. Adverse Effects of Treatments
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Indication
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Prostate Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Benign Prostatic Hyperplasia (BPH)
6.4. Prostatitis
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Radiation Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chemotherapy
7.4. Immunotherapy
7.5. Hormone Therapy
7.6. Targeted Drug Therapy
7.7. Others
8. By End Users
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
8.1.2. Market Attractiveness Index, By End Users
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oncology Centers
8.4. Ambulatory Surgical Centers
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
Key Market Players
11.1. Novartis AG*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals etc.
11.1.5. SWOT Analysis
11.2. GSK plc.
11.3. Astellas Pharma Inc.
11.4. Merck & Co., Inc.
11.5. JOHNSON & JOHNSON SERVICES, INC.
11.6. Pfizer Inc.
11.7. Sanofi SA
11.8. Bayer
11.9. Zydus Lifesciences Limited
11.10. Wellona Pharma
* Similar data will be provided for each market player.
Emerging Market Players
11.11. Candel Therapeutics, Inc.*
11.11.1. Pipeline Products Description
11.11.2. Product Key Performance Indicators (KPIs)
11.11.3. Key Activities
11.11.4. Market Entry Timelines
11.11.5. Product Penetration Rate
11.11.6. Sales Estimation and Projections
11.12. Essa Pharma
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us